MedicalResearch.com Interview with:
Ziyad Al-Aly MD FASN
Assistant Professor of Medicine
Co-director for Clinical Epidemiology Center
Department of Medicine, Washington University School of Medicine
Saint Louis, Missouri
Associate Chief of Staff for Research and Education
Veterans Affairs Saint Louis Health Care System
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Proton Pump Inhibitors (PPI) are commonly used, and they are associated with adverse events including kidney disease, dementia, fractures, cardiovascular disease, and pneumonia. We asked the question of whether this translates to increased risk of death.
We conducted this large cohort study to specifically examine the association between PPI use and risk of death. The results consistently showed an association between use of PPI and increased mortality risk. Moreover, there was a graded relationship between duration of PPI use and risk of death in that longer duration of use was associated with incrementally higher risk of death.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: That Proton Pump Inhibitors are associated with adverse events, and that PPI use may also be associated with higher risk of death. PPI use should be considered carefully; prolonged or extended use should be restricted to situations where there is a clear medical indication.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: We need to better understand which patients (or groups of patients) are at highest risk of experiencing adverse events related to PPI use.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.